{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:47:03Z","timestamp":1792032423588,"version":"4.4.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2008,8,12]],"date-time":"2008-08-12T00:00:00Z","timestamp":1218499200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s00417-008-0914-4","type":"journal-article","created":{"date-parts":[[2008,8,11]],"date-time":"2008-08-11T14:25:19Z","timestamp":1218464719000},"page":"1699-1705","source":"Crossref","is-referenced-by-count":112,"title":["Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy"],"prefix":"10.1007","volume":"246","author":[{"given":"Siamak","family":"Moradian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Ahmadieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Malihi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Soheilian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hossein","family":"Dehghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Azarmina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,8,12]]},"reference":[{"key":"914_CR1","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0161-6420(91)32085-2","volume":"98","author":"JF Vander","year":"1991","unstructured":"Vander JF, Duker JS, Benson WE, Brown GC, McNamara JA, Rosenstein RB (1991) Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretianl photocoagulation. Ophthalmology 98:1575\u20131579","journal-title":"Ophthalmology"},{"key":"914_CR2","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1001\/archopht.1985.01050110037019","volume":"103","author":"The Diabetic Retinopathy Vitrectomy Study Research Group","year":"1985","unstructured":"The Diabetic Retinopathy Vitrectomy Study Research Group (1985) Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol 103:1643\u20131644","journal-title":"Arch Ophthalmol"},{"key":"914_CR3","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0161-6420(88)33015-0","volume":"95","author":"The Diabetic Retinopathy Vitrectomy Study Research Group","year":"1988","unstructured":"The Diabetic Retinopathy Vitrectomy Study Research Group (1988) Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision, results of a randomized trial. Diabetic Retinopathy Vitrectomy Study Report 3. Ophthalmology 95:1307\u20131320","journal-title":"Ophthalmology"},{"key":"914_CR4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/01.icu.0000143685.60479.3b","volume":"15","author":"GM Comer","year":"2004","unstructured":"Comer GM, Ciulla TA (2004) Pharmacotherapy for diabetic retinopathy. Curr Opin Ophthalmol 15:508\u2013518, doi: 10.1097\/01.icu.0000143685.60479.3b","journal-title":"Curr Opin Ophthalmol"},{"key":"914_CR5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2337\/diacare.23.4.504","volume":"23","author":"MB Grant","year":"2000","unstructured":"Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S et al (2000) The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care 23:504\u2013509, doi: 10.2337\/diacare.23.4.504","journal-title":"Diabetes Care"},{"key":"914_CR6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/s-2001-15282","volume":"33","author":"BO Boehm","year":"2001","unstructured":"Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE (2001) Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 33:300\u2013306, doi: 10.1055\/s-2001\u201315282","journal-title":"Horm Metab Res"},{"key":"914_CR7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581\u2013611, doi: 10.1210\/er.2003\u20130027","journal-title":"Endocr Rev"},{"key":"914_CR8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00006982-200502000-00001","volume":"25","author":"AP Adamis","year":"2005","unstructured":"Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111\u2013118, doi: 10.1097\/00006982\u2013200502000\u201300001","journal-title":"Retina"},{"key":"914_CR9","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480\u20131487, doi: 10.1056\/NEJM199412013312203","journal-title":"N Engl J Med"},{"key":"914_CR10","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archopht.1996.01100140172010","volume":"114","author":"MJ Tolentino","year":"1996","unstructured":"Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP (1996) Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 114:964\u2013970","journal-title":"Arch Ophthalmol"},{"key":"914_CR11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archopht.1996.01100130062010","volume":"114","author":"AP Adamis","year":"1996","unstructured":"Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J et al (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114:66\u201371","journal-title":"Arch Ophthalmol"},{"key":"914_CR12","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.ophtha.2006.05.064","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA et al (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113:1695\u20131705 doi: 10.1016\/j.ophtha.2006.05.064","journal-title":"Ophthalmology"},{"key":"914_CR13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275\u2013278, doi: 10.1097\/00006982\u2013200603000\u201300004","journal-title":"Retina"},{"key":"914_CR14","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0161-6420(13)38014-2","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","unstructured":"Early Treatment Diabetic Retinopathy Study Research Group (1991) Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 98:823\u2013833","journal-title":"Ophthalmology"},{"issue":"9","key":"914_CR15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/01.iae.0000246884.76018.63","volume":"26","author":"R Jorge","year":"2006","unstructured":"Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU (2006) Intravitreal Bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 26(9):1006\u20131013, doi: 10.1097\/01.iae.0000246884.76018.63","journal-title":"Retina"},{"key":"914_CR16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","volume":"26","author":"RL Avery","year":"2006","unstructured":"Avery RL (2006) Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 26:352\u2013354, doi: 10.1097\/00006982\u2013200603000\u201300016","journal-title":"Retina"},{"key":"914_CR17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/bjo.2007.127142","volume":"92","author":"JF Arevalo","year":"2008","unstructured":"Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L et al (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213\u2013216, doi: 10.1136\/bjo.2007.127142","journal-title":"Br J Ophthalmol"},{"key":"914_CR18","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00006982-200603000-00017","volume":"26","author":"FH Davidorf","year":"2006","unstructured":"Davidorf FH, Mouser JG, Derick RJ (2006) Rapid improvement of rubeosis Iridis from a single bevacizumab injection. Retina 26:354\u2013356, doi: 10.1097\/00006982\u2013200603000\u201300017","journal-title":"Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-008-0914-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-008-0914-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-008-0914-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T19:40:41Z","timestamp":1559072441000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-008-0914-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,12]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["914"],"URL":"https:\/\/doi.org\/10.1007\/s00417-008-0914-4","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,12]]}}}